



# Supplementary Figure S1


Chen *et al*



CTLA-4 Blockade




Pre-treatment



# Supplementary Figure 3

Chen *et al*




**b**

Treatment Timepoint	% Contact Between CD8 and CD68 Cells		
	Responders (n)	Non-Responders (n)	p-value
<b>CTLA-4 Blockade</b>			
Pre-treatment	<10% (2)	30-40% (3)	0.08
On treatment	10-20% (1)	30-40% (1)	N/A
<b>PD-1 Blockade</b>			
Pre-treatment	10-20% (3)	50-60% (3)	0.0495
On treatment	<10% (3)	30-40% (3)	0.0495


# Supplementary Figure S4

Chen *et al*




# Supplementary Figure 5

Chen *et al*



# Supplementary Figure 6



Chen *et al*



# Supplementary Figure S7

Chen *et al*


a




# Supplementary Figure S8

Chen *et al*


## PD-1 Blockade



## Pre-treatment




## On-treatment





# Supplementary Figure S9


Chen *et al*



# Supplementary Figure 10

Chen *et al*


## CTLA-4 Blockade



# Supplementary Figure 11

Chen *et al*

## PD-1 Blockade




# Supplementary Figure S12


Chen *et al*

## Pre-treatment

### Responders




### Non-Responders




## On treatment


### Responders



### Non-Responders



α-CTLA-4 naïve  
Prior α-CTLA-4



# Supplementary Figure S13

Chen *et al*

